124 related articles for article (PubMed ID: 25628391)
1. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
[TBL] [Abstract][Full Text] [Related]
4. Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection.
Shimizu Y; Yoneda K; Shirasago Y; Suzuki T; Tada M; Ishii-Watabe A; Sugiyama K; Suzuki T; Wakita T; Yagi K; Kondoh M; Fukasawa M
Biochem Biophys Res Commun; 2019 Jun; 514(3):785-790. PubMed ID: 31079928
[TBL] [Abstract][Full Text] [Related]
5. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.
Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C
J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
[TBL] [Abstract][Full Text] [Related]
7. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
[TBL] [Abstract][Full Text] [Related]
8. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
[TBL] [Abstract][Full Text] [Related]
9. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
10. Isolate-dependent use of claudins for cell entry by hepatitis C virus.
Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T
Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920
[TBL] [Abstract][Full Text] [Related]
11. A human claudin-1-derived peptide inhibits hepatitis C virus entry.
Si Y; Liu S; Liu X; Jacobs JL; Cheng M; Niu Y; Jin Q; Wang T; Yang W
Hepatology; 2012 Aug; 56(2):507-15. PubMed ID: 22378192
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model.
Hashimoto Y; Tada M; Iida M; Nagase S; Hata T; Watari A; Okada Y; Doi T; Fukasawa M; Yagi K; Kondoh M
Biochem Biophys Res Commun; 2016 Aug; 477(1):91-95. PubMed ID: 27286708
[TBL] [Abstract][Full Text] [Related]
13. Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins.
Hopcraft SE; Evans MJ
Hepatology; 2015 Oct; 62(4):1059-69. PubMed ID: 25820616
[TBL] [Abstract][Full Text] [Related]
14. Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I.
Arvieux J; Roussel B; Pouzol P; Colomb MG
Thromb Haemost; 1993 Aug; 70(2):336-41. PubMed ID: 8236145
[TBL] [Abstract][Full Text] [Related]
15. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
[TBL] [Abstract][Full Text] [Related]
16. Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency.
Scallon B; Cai A; Radewonuk J; Naso M
Mol Immunol; 2004 May; 41(1):73-80. PubMed ID: 15140577
[TBL] [Abstract][Full Text] [Related]
17. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J
J Virol; 2018 May; 92(10):. PubMed ID: 29491159
[TBL] [Abstract][Full Text] [Related]
18. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of retroviral infection in vitro by anti-Le(y) IgG: reversal by humanization of monoclonal mouse antibody.
Hansen JE; Sørensen AM; Arendrup M; Olofsson S; Nielsen JO; Janzek E; Nielsen C; Loibner H
APMIS; 1993 Sep; 101(9):711-8. PubMed ID: 7902106
[TBL] [Abstract][Full Text] [Related]
20. Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.
Haid S; Windisch MP; Bartenschlager R; Pietschmann T
J Virol; 2010 Jan; 84(2):964-75. PubMed ID: 19889758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
